RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
Part of paid clinical trials in Gainesville, Florida.
- Sponsor
- University of Florida
- Study ID
- NCT06389591
- Phase
- PHASE1
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1) — BIOLOGICALpp65 RNA loaded lipid particles or pp65 RNA-LPs administered intravenously
- RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2) — BIOLOGICALpersonalized tumor mRNA, pp65 fl LAMP mRNA and DOTAP liposomes or RNA loaded lipid particles, RNA-LPs administered intravenously
Study Details
This is a Phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma.
Key Dates
- Start date
- Dec 2, 2024
- Status verified
- May 2026
- Primary completion
- Dec 1, 2026
- Completion
- Dec 1, 2027
Study Design
- Enrollment
- 24 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm 1: pp65 RNA-LPs (DP1) before biopsyParticipants will receive pp65 RNA-LPs (DP1) starting before tumor biopsy/resection. All patients will receive three pp65 RNA-LP vaccines (DP1) before receiving full dose monthly RNA-LPs (RNA loaded lipid particles, RNA-LPs, DP2).
Primary Outcome Measure
Percentage of vaccines meeting release criteria in the DLT window during the first three vaccines [ Time Frame: from the date of surgery until administration of third vaccine, up to 20 weeks ]
Central Contacts
- Phuong Deleyrolle352-273-5519
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UF Health | Gainesville | Florida | 32608 | Ashley Ghiaseddin, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Gainesville, FL
By condition
By specialty
By research site
Related Studies
- Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent GlioblastomaRecruiting · University of Miami · Miami, Florida
- A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBMPHASE1 · Recruiting · Boston Scientific Corporation · Birmingham, Alabama
- Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBMPHASE3 · Recruiting · CarThera · Phoenix, Arizona
- Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent GlioblastomaPHASE2 · Recruiting · Academic and Community Cancer Research United · Scottsdale, Arizona